Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. OSE Immunotherapeutics
  6. News
  7. Summary
    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OSE Immunotherapeutics : to Host Today a Virtual “Immuno-Oncology R&D Day”

10/12/2021 | 01:30am EST
  • R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;
  • Presentations by leading clinicians to feature the latest data on Tedopi® and BI 765063.

NANTES, France, Oct. 12, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) will host a virtual R&D Day on Tuesday, October 12th, 2021 at 4:00 p.m. CEST/ 10:00 a.m. EDT.

Date: Tuesday, October 12th, 2021
Time: 4:00 p.m. - 7:00 p.m. CEST / 10:00 a.m. - 1:00 p.m. EDT

Details for the virtual R&D Day : 

The live webcast of the event will be available from 3:30 p.m. CEST / 9:30 a.m. EDT
at the following link:
https://www.financelive.fr/oseo-immuno/inscription/

A replay of the webcast following the event will be available for 90 days on the Company’s website:
https://ose-immuno.com/en/

The event, which will feature presentations by leading clinicians as well as key members of the OSE Immunotherapeutics management team, will provide an update on:

  • The Company’s strategy to build a leading portfolio of best- and first-in-class cancer immunotherapies.
  • OSE’s goal to position Tedopi® as a new standard of care in non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure and its ongoing clinical development as a maintenance therapy for ovarian and pancreatic cancers.
  • Recent clinical data supporting development of first-in-class CD47/SIRPα pathway targeting antibody BI 765063 alone and in combination with anti-PD-1 ezabenlimab in solid tumours.
  • OSE’s emerging best- and first-in-class immuno-oncology portfolio which includes a novel myeloid cell “Don’t Eat Me” signal targeting CLEC-1 and a bispecific antibody platform (BiCKI®) whose first candidate, BiCKI®-IL-7 both combines an anti-PD-1 and the cytokine signal interleukin-7 (IL-7).

Amongst the R&D Day’s key speakers are:

  • Pr. Benjamin Besse, Director of Clinical Research at Gustave Roussy (Villejuif, France), will present the positive final results of the Phase 3 Tedopi® clinical program in NSCLC, called Atalante-1, as well as an overview of the current landscape in NSCLC post-ICI.
  • Dr. Philippe Cassier, Medical Oncologist at Leon Berard Cancer Center (Lyon, France), will highlight Phase 1 results of BI 765063 alone and in combination with ezabenlimab.

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:
Vaccine platform

  • Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive final results of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients after secondary resistance to checkpoint inhibitors.
    In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
    In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
    In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).

Immuno-oncology platform

  • BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening.
  • CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
  • BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.

Auto-immunity and inflammation platform

  • FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the Nantes University Hospital); Phase 2-ready asset in an autoimmune disease indication.
  • OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a is being conducted in Sjögren’s syndrome (Servier sponsor).
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

For more information: https://ose-immuno.com/en/

Click and follow us on Twitter and Linkedln
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673

Contacts

OSE Immunotherapeutics
Sylvie Détry
sylvie.detry@ose-immuno.com
+33 153 198 757


Investor Relations
Thomas Guillot
thomas.guillot@ose-immuno.com
+33 607 380 431
Media
U.S. Media: LifeSci Communications
Darren Opland, Ph.D.
darren@lifescicomms.com
+1 646 627 8387

French Media: FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 607 768 283

Guillaume van RenterghemLifeSci Advisors
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2021, including the annual financial report for the fiscal year 2020, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.


Primary Logo

Source: OSE Immunotherapeutics

2021 GlobeNewswire, Inc., source Press Releases

All news about OSE IMMUNOTHERAPEUTICS
01/17OSE Immunotherapeutics CEO Resigns, Interim Successor Named
MT
01/17OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO..
AQ
01/17OSE Immunotherapeutics SA Announces CEO Change
CI
2021OSE Immunotherapeutics Strengthens Leadership Teamáwith the Appointment of Laurence de ..
GL
2021OSE Immunotherapeutics Strengthens Leadership Teamáwith the Appointment of Laurence de ..
GL
2021OSE Immunotherapeutics Adds Chief Business Officer To Bolster Drug Development
MT
2021OSE Immunotherapeutics Sa Announces Executive Changes
CI
2021OSE IMMUNOTHERAPEUTICS : Nomination
CO
2021OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-I..
CI
2021GLOBAL MARKETS LIVE : General Motors, JP Morgan, Pfizer, Novavax, Ford...
More news
Analyst Recommendations on OSE IMMUNOTHERAPEUTICS
More recommendations
Financials
Sales 2021 16,8 M 19,1 M 19,1 M
Net income 2021 -17,9 M -20,3 M -20,3 M
Net Debt 2021 - - -
P/E ratio 2021 -9,41x
Yield 2021 -
Capitalization 167 M 190 M 190 M
Capi. / Sales 2021 9,95x
EV / Sales 2022 1,85x
Nbr of Employees 53
Free-Float 63,4%
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | OSE | FR0012127173 | MarketScreener
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 9,17 €
Average target price 16,52 €
Spread / Average Target 80,2%
EPS Revisions
Managers and Directors
Dominique Costantini Chairman & Chief Executive Officer
Anne-Laure Autret-Cornet Chief Financial & Administrative Officer
Nicolas Poirier Chief Scientific Officer & Director
Silvia Comis Head-Clinical Development
Laurence de Schoulepnikoff Chief Operating & Business Officer
Sector and Competitors
1st jan.Capi. (M$)
OSE IMMUNOTHERAPEUTICS-10.80%190
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508